Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
William Pridgen Insider Profile
11 Followers
William Pridgen, Director at Virios Therapeutics, holds 761.28K shares in Virios Therapeutics (Ticker: VIRI). Most recently, William Pridgen Bought $15,335 shares of Virios Therapeutics on Aug 22, 2023 for an estimated value of 19.94K.
Profitable Transactions
0 out of 10 Profitable Transactions
Average Return
-63.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of William Pridgen's holdings
Insider Roles
Director
Roles that William Pridgen holds in companies
Most Profitable Insider Trade
The most profitable trade made by William Pridgen
William Pridgen's Trading History
List of latest transactions for each holding click on a transaction to see William Pridgen's performance on stock
You May Also Like
William Pridgen insider profile FAQ
What is the percentage of profitable transactions made by William Pridgen?
The percentage of profitable transactions made by William Pridgen is 0%.
What is the average return per transaction made by William Pridgen?
The average return per transaction made by William Pridgen is -63.70%.
What stocks does William Pridgen hold?
William Pridgen holds: VIRI stocks.
What was William Pridgen’s latest transaction?
William Pridgen latest transaction was an Informative Buy of $19.94K.
What was William Pridgen's most profitable transaction?
William Pridgen’s most profitable transaction was an Informative Buy of VIRI stock on February 1, 2021. The return on the trade was -1.60%.
What is William Pridgen's role in Virios Therapeutics?
William Pridgen's role in Virios Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.